Who We Are
Patients are at the heart of all we do.
Harmony Biosciences is an innovative biopharmaceutical company dedicated to developing and commercializing novel treatment options for patients with rare diseases. With an emphasis on central nervous system disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.
What We Believe
Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.
Our Leadership
Our company is led by a passionate team of industry veterans with a proven track record of success in developing and commercializing novel treatments for patients.
PRESS RELEASES
October 9, 2018
New Survey Identifies Need For Increased Education About And New Treatment Options For Narcolepsy
Read More
SEPTEMBER 27, 2018
Data On Abuse Potential Of Pitolisant Presented At 2018 European Sleep (ESRS) Congress
Read More
SEPTEMBER 12, 2018
Harmony Biosciences Celebrates Ribbon Cutting At Plymouth Meeting Headquarters With Pennsylvania Governor Tom Wolf
Read More
SEPTEMBER 10, 2018
Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
Read More
SEPTEMBER 5, 2018
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming International Narcolepsy Symposium
Read More
MAY 31, 2018
Harmony Biosciences To Present Data On Its Investigational Product, Pitolisant, At Upcoming SLEEP Annual Meeting
Read More
MAY 21, 2018
Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant
Expanded Access Program For Pitolisant Is Open
Read More
October 5, 2017
Harmony Biosciences Acquires US Rights To Pitolisant From Bioprojet; Raises $270 Million In Equity Financing
Read More
